Interestingly, erlotinib-treated patients with squamous tumors tended to live longer than patients with non-squamous EGFR wild-type carcinoma, which contradicts previous findings that the prognosis of adenocarcinoma patients is generally better than that of patients with squamous tumors [10]. This evidence concerns the gene EGFR and carcinoma.